Research library
Sources, with the status on the record.
Each row is a paper or a ClinicalTrials.gov entry checked on 21 November 2026. Titles are the authors’ or the registry’s words. Nalen Lab does not restate them as claims about these products. A registration is not a result.
Records checked 2026-11-21. Open registry rows in this view: 1. Selank has published papers and no verified intervention trial.
Loading filters…
MOTS-c
2015
Publication
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
Lee C et al. · Cell Metabolism
PublishedSame compound as the catalogue listing
Founding paper. Mouse and cell work. The title is the authors' wording.
View in the catalogueMOTS-c
2022
Publication
MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases.
Mohtashami Z et al. · International Journal of Molecular Sciences
PublishedSame compound as the catalogue listing
Review.
View in the catalogueMOTS-c
2026
Registry
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
Phase 2 · ClinicalTrials.gov · NCT07505745 · Hudson Biotech
RecruitingSame compound as the catalogue listing
Intervention named on the record is MOTS-c. Checked 21 November 2026. A registration is not a result.
View in the catalogueMOTS-c
2014
Registry
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Observational · ClinicalTrials.gov · NCT04027712 · University of Athens
UnknownMeasures or combines the compound; not a single-compound vial study
This record follows endogenous MOTS-c as a measured marker. It does not administer the peptide. Status Unknown. Not an active treatment trial.
View in the catalogue